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Abstract 46 
 47 
Hematological parameters have emerged as independent determinants of high serum 48 
concentrations of uric-acid and predictive-factors in the evaluation of the total 49 
cardiovascular-risk in patients with essential-hypertensive. Here we have investigated the 50 
possible relationships between hematological-factors and serum uric-acid levels in 51 
hypertensive-patients recruited as part of Mashhad-Stroke and Heart-Atherosclerotic-52 
Disorders cohort study. Two-thousand three-hundred and thirty four hypertensive individuals 53 
were recruited from this cohort and these were divided into two groups; those with either 54 
high or low serum uric acid concentrations. Demographic, biochemical and hematological 55 
characteristics of population were evaluated in all the subjects. Logistic-regression-analysis 56 
was performed to determine the association of hematological-parameters with hypertension. 57 
Of the 2334 hypertensive-subjects, 290 cases had low uric-acid, and 2044 had high serum 58 
uric acid concentrations. Compared with the low uric acid group, the patients with high serum 59 
uric acid, had higher values for several hematological parameters, whilst platelet counts 60 
(PLT) were lower. Multiple linear regression analysis showed that PLT and serum hs-CRP 61 
were correlated with serum uric acid level. Stepwise multiple logistic regression model 62 
confirmed that PDW and gender were independent determinant of a high serum uric acid. 63 
PDW and PLT appear to be independently associated with serum uric acid level in patients 64 
with hypertension. 65 
 66 
Key word: Hypertension, PDW, uric acid, biomarker 67 
68 
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Introduction 69 
Hypertension (HTN) is one of the major risk factors of cardiovascular disease 1. Recently 70 
Luo et al., showed that there is a significant positive association between hematological 71 
parameters and serum uric acid level in patients without antihypertensive treatment. 72 
hematological parameters were significantly different in hypertensive patients with high 73 
serum uric acid levels compared with those of low high uric acid level. Hematological 74 
parameters are suggested to be independent determinants of serum uric acid in newly 75 
diagnosed hypertensive2. Moreover, it is reported that some hematological parameters are 76 
correlated with higher systolic and diastolic blood pressures independently of age, 77 
inflammatory status and anemia 1.  78 
Against this background, it has recently being suggested that uric acid is a risk factor for 79 
cardiovascular disease 3. Uric acid is the end product of purine metabolism 4. Hyperuricemia 80 
is defined as a serum concentration  ≥7 mg/dL for men and ≥6 mg/dL for women.  Increased 81 
serum uric acid is found in postmenopausal women, African-American patients with renal 82 
disease and is related to alcohol intake. Several other factors can influence the concentrations 83 
of uric acid, e.g. diet, obesity, and Metabolic Syndrome 5. Moreover, it has been shown that 84 
an elevated serum uric acid is associated with an increased risk of CVD, all-cause mortality, 85 
and new-onset diabetes in hypertensive patients 4. Hyperuricemia is also associated with the 86 
inflammatory process. Some inflammatory cytokines may activate xanthine oxidase enzyme 87 
in epithelial cells, causing serum uric acid to increase. The inflammatory status is also related 88 
to ineffective erythropoiesis, and it has been suggested that inflammatory cytokines, such as 89 
interleukin (IL)-1 β, IL-6, tumor necrosis factor (TNF)-α, desensitize bone marrow erythroid 90 
progenitors to erythropoiesis, inhibit red blood cell maturation and thereby promote 91 
anisocytosis 3. 92 
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Recently, the relationship between hematological indices, serum level of uric acid and 93 
hypertension have received new interest. The aim of the present study was to investigate the 94 
relationships between hematological factors, specifically hematological parameters, and 95 
serum uric acid concentrations in individuals with and without hypertension, recruited as part 96 
of the Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study. 97 
Methods  98 
Population  99 
In the current study, 2334 hypertensive individuals were recruited from the Mashhad stroke 100 
and heart atherosclerotic disorder (MASHAD) study 6-7. All participants providedinformed 101 
written consent. The study was approved by ethics committee of Mashhad University of 102 
Medical Sciences Mashhad, Iran. 103 
Individuals were categorized based on blood pressure measurements and serum uric acid 104 
levels. Those who had systolic blood pressure ≥140 mmHg and/or diastolic blood pressure 105 
≥90 mmHg were defined as Hypertensive. Low (<4.8 µmol/L) and high (≥4.8 µmol/L) uric 106 
acid groups were defined based on serum uric acid concentration. Hence the patients were 107 
classified into 4 groups: non-hypertensive patients who had low level of serum uric acid, non-108 
hypertensive patients who had high level of serum uric acid, hypertensive patients who had 109 
low level of serum uric acid, and hypertensive patients who had high level of serum uric acid. 110 
All methods were performed in accordance with the relevant guidelines and regulations and 111 
with approval of Mashhad university of Medical Sciences. 112 
Anthropometric measurements: 113 
Height, body weight, and waist circumference (WC) were measured as previously described 114 
7-86,7. Body Mass Index (BMI), systolic and diastolic blood pressures (BP) were evaluated as 115 
reported recently9-10.  116 
Biochemical parameters: 117 
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Serum levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol 118 
(HDL-C), high sensitive C-reactive protein (hs-CRP), uric acid (UA), low-density lipoprotein 119 
cholesterol (LDL-C) and fasting blood glucose (FBG) were measured as previously described 120 
11-138. 121 
Hematological parameters: 122 
Hematological indices including white blood cells count (WBC), red blood cells count 123 
(RBC), platelets count (PLT), hemoglobin concentration (HGB), hematocrit (HCT), mean 124 
corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), mean 125 
corpuscular hemoglobin (MCH), red blood cell distribution width (RDW) and platelet 126 
distribution width (PDW) were measured using a Sysmex K800 automated cell counter 127 
(Sysmex Inc. United States), as described recently14-16. 128 
Statistical analysis: 129 
Statistical Package for Social Sciences (SPSS; version 20 for Windows) was used to analyze 130 
data. Student’s T-test and chi-squared test were used for understanding the differentiation 131 
between qualitative and quantitative variables, respectively. Pearson’s correlation coefficients 132 
were counted between uric acid and other parameters. Continuous data are expressed as 133 
means ± Standard deviations (SD)17. P values below 0.05 were considered as statistically 134 
significant in all applied tests. 135 
Results: 136 
Demographic and clinical characteristics of the population: 137 
Of the total number of 9749 subjects recruited into the MASHAD study, 2334 subjects with 138 
hypertension were identified of whom 290 had a low serum uric acid level and 2044 had a 139 
high serum uric acid. Demographic and clinical characteristics of the population are 140 
described in Table 1. We observed a significant difference for age, Sex, BMI, HDL, TG, 141 
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FBG, RBC, HGB, HCT, PLT, MCH and platelet size variability between groups defined by 142 
low/high uric acid (Table 1). 143 
Correlation assessment in hypertensive patients: 144 
Correlation analysis indicated that serum uric acid concentrations were positively related to 145 
hs-CRP, BMI, TG, MCH, WBC, RBC, HGB, HCT, cholesterol and age. An inverse 146 
relationship was found between serum uric acid and FBG, HDL-C, and PLT. These findings 147 
are described in Table 2-3. 148 
Regression analysis for serum uric acid levels in hypertension patients: 149 
The collinearity analysis showed that there are apparent multi-collinearities among variables. 150 
In a stepwise multiple linear regression analysis, age, gender, BMI, HDL-C, cholesterol, 151 
FBG, TG, hs-CRP, and PLT were statistically significant factors (Table 3). Multiple linear 152 
regression analysis for effects of independent variables on serum uric acid level in 153 
hypertensive patients are shown in Table 4. These data showed an association of age, gender, 154 
BMI, serum fasted cholesterol and triglycerides (TG), FBG, and PDW with serum uric acid 155 
in patients with untreated essential hypertension (Table 4). 156 
Discussion 157 
To the best of our knowledge this is the first cohort study evaluating and validating the 158 
association of hematological parameters, including WBC, RBC, HGB, HCT, MCV, MCH, 159 
MCHC, RDW, PLT and platelet size variability (PDW) with serum uric acid concentrations 160 
in individuals with hypertension. Our findings showed a significantly positive association 161 
between hs-CRP, and PLT and serum uric acid level in patients without antihypertensive 162 
treatment. PLT and PDW were identified as independent determinants of a high serum uric 163 
acid in newly diagnosed hypertensive.  164 
Hyperuricemia is an indirect indicator of increased oxidative stress. During the synthesis of 165 
uric acid, hydrogen peroxide is generated18. It is not known whether uric acid would be a 166 
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causal factor or an antioxidant protective response against oxidative stress. While chronic 167 
high uric acid concentrations are associated with an increased risk for coronary artery disease 168 
(CAD), acute elevations seem to provide antioxidant protection 5. The increased serum uric 169 
acid levels in hypertensive patients may be due to the decline in renal blood flow that is 170 
associated with hypertension; reduced renal blood flow may be associated with a reduced 171 
urate excretion18. Several mechanisms have been proposed for the association between serum 172 
uric acid and cardiovascular and renal abnormalities, including: (1) increased uric acid 173 
production that may counteract oxidative stress and endothelial damage in the context of the 174 
atherosclerotic process; (2) the severity of hypertension itself; (3) a subtle reduction in 175 
glomerular filtration rate leading to impaired renal uric acid clearance19. Moreover it has been 176 
documented that higher WC and BMI are associated with higher insulin resistance and leptin 177 
production, and both reduce renal uric acid excretion, thus increasing its serum concentration. 178 
HDL-C concentration is negatively associated with insulin resistance, which in turn can 179 
influence its negative correlation to uric acid 5. These data are in accord with our findings. 180 
Furthermore we found a significant relationship between serum uric acid and serum hs-CRP 181 
in the hypertensive group. Ruggiero et al suggested that serum uric acid has positive 182 
relationship with inflammatory markers such as WBC, CRP, IL-6, IL-18, and TNF-α. Briefly, 183 
in inflammatory related diseases, chronic hypoxia causes cellular damage that upregulates the 184 
xanthine oxidase enzyme, leading to parallel increase of uric and free radical production, 185 
resulting into endothelial dysfunction20. Peng-Fei Li et al have shown that WBC and HGB 186 
are associated with metabolic syndrome21, which is agreement with our data indicating that, 187 
WBC, and RBC were higher in hypertensive subjects compared to non-hypertensive ones. 188 
Additionally normocytic anemia is common among hypertensive patients. Lower hemoglobin 189 
concentrations were found in patients with uncontrolled than among those with well 190 
controlled hypertension, indicating a higher cardiovascular risk in uncontrolled 191 
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hypertension22. In this study HGB and HCT mean values did not differ significantly between 192 
hypertensive hyperuricemic subjects and non-hypertensive hyperuricemic subjects.  193 
Of note we did not observe a significant association between RDW and uric acid. However, 194 
several other studies have suggested that RDW may be associated with vascular disorders, 195 
myocardial infarctions, stable angina, chronic heart failure, stroke, pulmonary 196 
thromboembolism, renal disease, malnutrition, neoplastic metastases to bone marrow and 197 
hypertension. In particular Tanindi et al., showed that RDW was higher in pre-hypertensive 198 
and hypertensive patients compared to healthy controls independently of age, inflammatory 199 
status and anemia. Moreover, higher RDW values were strongly correlated with higher 200 
systolic and diastolic blood pressures 1. Min Luo et al. have shown that RDW may be a more 201 
sensitive indicator for predicting uric acid level than CRP 3. However, in this study RDW was 202 
not correlated with serum uric acid level in hypertensive patients. This discrepancy can be 203 
explained at least in part by low sample size of most studies, ethnicity and possible influence 204 
of life style on hematological markers, although in the present study we explore the value of 205 
these markers in a large cohort study. 206 
Increased platelet counts were reported in several studies in subjects with metabolic 207 
syndrome, atherosclerosis and CVD34-36. Additionally, several other studies have reported a 208 
relationship between  PDW, MPV and PLT with blood pressure and hypertension 29, 209 
pulmonary arterial hypertension37, pregnancy induced hypertension of preeclampsia, severe 210 
preeclampsia and eclampsia30. PDW shows the variation of the platelet size and May marker 211 
is more useful than MPV in providing platelet activity. Platelets play key roles in 212 
inflammation pathway via their activity to increase vascular permeability, atherosclerosis and 213 
cardiovascular events39.40. 214 
 On the other hand, inconsistent results have reported by Luca and colleague that PDW had 215 
no significant association with the prevalence and development of CAD31. While other 216 
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studies showed an association between platelet size variability and serum uric acid in 217 
myocardial infarction32 and neonatal sepsis33. Serum uric acid plays a key role to activate 218 
leukocyte and can lead to stimulation of inflammatory responses and  to endothelial injury33.  219 
However,a positive association between increased uric acid levels and higher concentrations 220 
of inflammatory factors have been reported39. However, this is the first study demonstrating 221 
association of PDW with uric acid in patients with hypertensive that can be used as risk 222 
predictor of HTN.  223 
We have found associations between age, gender, BMI, HDL-C, cholesterol, FBG, TG, hs-224 
CRP, PLT and PDW with serum uric acid in hypertensive individuals. There was a 225 
significant relationship between serum uric acid level and hs-CRP in these patients, 226 
suggesting the role of inflammation in hypertension process. The possible interaction 227 
between blood viscosity, inflammation and uric acid, which in conjunction with high blood 228 
pressure may have an adverse impact on endothelial function and so become a risk factors for 229 
future events, which is in line with previous observation24-28. In particular Puddu et al., 230 
explored the association of serum uric acid with the incidence of coronary and cardiovascular 231 
events in an Italian population. They showed that increased serum uric acid levels and RBC 232 
was independently related with risk of CVD events in the 6-year follow-up of the Gubbio 233 
Study24-25. Another study by this research group also showed the value of serum uric acid as a 234 
predictor of long-term incidence of cardiovascular events and deaths26. In aggregate, further 235 
studies in prospective setting are warranted to explore the value of emerging marker as risk 236 
stratification factor. 237 
 238 
 239 
 240 
 241 
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Table 1: demographic and clinical charateric of population 
 high uric acid(2044) low uric acid(290) P-value 
Age (y) 52.19±7.96 50.91±7.60 0.01 
Sex Female: 903(44.2%) 
Male: 1140(55.8%) 
Female: 54(19.9%) 
Male:218(80.1%) 
<0.001 
BMI (Kg/m2) 29.38±4.70 28.44±4.60 0.002 
Smoking status No-smoker:1424(69.7%) 
Ex-smoker:234(11.4%) 
Current smoker: 386(18.9%) 
No-smoker: 189(69.5%) 
Ex-smoker:33(12.1%) 
Current smoker:50(18.4%) 
0.93 
LDL (mg/dL) 120.29±37.50 119.71±33.25 0.8 
HDL (mg/dL) 42.73±9.77 45.07±11.63 0.002 
TG mg/ dL) 141(101-197) 109(78-143) <0.001 
Cholesterol 200.18±40.94 191.71±38.00 0.001 
FBG (mg/dL) 98.65±42.48 118.47±63.91 <0.001 
Hs-CRP 2.02(1.19-4.43) 1.63(1.11-3.71) 0.09 
SBP (mm Hg) 145.56±19.42 145.63±16.63 0.95 
DBP (mm Hg) 93.02±8.68 93.99±22.03 0.47 
WBC(109/L) 6.23±1.55 6.09±1.54 0.17 
RBC(1012/L) 4.96±0.48 4.78±0.43 <0.001 
HGB(g/dl) 13.96±1.53 13.35±1.59 <0.001 
HCT(%) 41.92±3.77 40.41±4.93 <0.001 
PLT(109/L) 229.54±62.39 246.46±71.36 <0.001 
RDW(%) 41.49±3.07 41.32±2.83 0.34 
PDW (%) 12.95±3.55 12.48±1.82 0.04 
MCV(fl) 84.63±6.03 84.08±5.86 0.15 
MCH(pg/cell) 28.29±2.35 27.91±2.72 0.03 
MCHC(g/dl) 33.25±1.80 33.15±1.59 0.38 
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Table 2. Correlation coefficient between serum uric acid concentration and 
other variables in patients with untreated essential hypertension 
 Correlation coefficient P value 
Age 0.06 0.002 
BMI 0.09 <0.001 
HDL-C -0.13 0.001 
FBG -0.171 <0.001 
TG 0.27 <0.001 
LDL-C -0.009 0.67 
Cholesterol 0.09 <0.001 
SBP 0.03 0.19 
DBP 0.02 0.33 
hs-CRP 0.08 <0.001 
WBC 0.08 <0.001 
RBC 0.17 <0.001 
HGB 0.18 <0.001 
HCT 0.20 <0.001 
MCV 0.03 0.16 
MCH 0.05 0.02 
RDW 0.01 0.62 
MCHC 0.007 0.74 
PDW 0.03 0.19 
PLT -0.10 <0.001 
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Table 3. Stepwise multiple linear regression analysis for the effect of 
independent variables on serum uric acid 
 B S.E. t P value 
constant 3.16 0.303 10.33 <0.001 
Age 0.012 0.003 3.48 0.001 
Gender -0.94 0.059 -15.97 <0.001 
BMI 0.05 0.006 8.49 <0.001 
HDL-C -0.006 0.003 -2.07 0.04 
Cholesterol 0.003 0.001 4.43 <0.001 
FBG -0.005 0.001 -8.49 <0.001 
TG 0.003 0.000 10.66 <0.001 
hs-CRP 0.012 0.003 4.067 <0.001 
PLT -0.001 0.000 -2.397 0.012 
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Table 4. Stepwise multiple logistic regression for uric acid in patients with untreated essential hypertension 
 B S.E. Wald P value Odd ratio 95%CI 
Age 0.022 0.01 5.40 0.02 1.02 1.004-1.042 
Gender 1.27 0.2 39.49 <0.001 3.56 2.39-5.29 
BMI 0.07 0.016 18.91 <0.001 1.07 1.04-1.11 
Cholesterol 0.006 0.002 7.66 0.006 1.006 1.002-1.011 
FBG -0.012 0.001 77.035 <0.001 0.99 0.98-0.99 
TG 0.009 0.001 35.82 <0.001 1.009 1.006-1.01 
PDW 0.104 0.043 5.89 0.01 1.10 1.02-1.21 
Constant -6.44 2.34 7.56 0.006   
 372 
 373 
 374 
